NASDAQ: CGCCanopy Growth Corp Stock
$0.95-0.01 (-1.04%)
Updated Jun 23, 2026
CGC Price
$0.95
Fair Value Price
-$0.39
Market Cap
$399.36M
52 Week Low
$0.84
52 Week High
$2.38
P/E
-1.48x
P/B
0.79x
P/S
1.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$206.23M
Earnings
-$190.51M
Gross Margin
24.5%
Operating Margin
-92.37%
Profit Margin
-92.4%
Debt to Equity
0.6
Operating Cash Flow
-$46M
Beta
1.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGC Overview
Canopy Growth Corporation (CGC), alongside its affiliated businesses, specializes in the cultivation, marketing, and retail of both cannabis and hemp-derived products. These offerings are designed for both recreational consumption and therapeutic uses, with its primary commercial reach extending across Canada, the United States, and Germany. The company structures its operations into two main divisions: Global Cannabis and a diverse portfolio of Other Consumer Products. Its extensive product range features dried cannabis flower, various extracts and concentrates, infused beverages, edible gummies, and vape cartridges. Canopy Growth distributes these items under numerous well-known brands, such as Tweed, 7ACRES, Martha Stewart CBD, and Spectrum Therapeutics, among others. Originally founded as Tweed Marijuana Inc., the enterprise adopted its current name, Canopy Growth Corporation, in September 2015. Established in 2009, the firm maintains its corporate headquarters in Smiths Falls, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CGC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CGC
Ranked#46 of 50
Ranked#46 of 50
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $161.44 | A | |
| $39.96 | A | |
| $82.94 | A |
Be the first to know about important CGC news, forecast changes, insider trades & much more!
CGC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CGC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGC ($0.95) is overvalued by 341.58% relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CGC ($0.95) is not significantly undervalued (341.58%) relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CGC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CGC due diligence checks available for Premium users.
Valuation
CGC fair value
Fair Value of CGC stock based on Discounted Cash Flow (DCF)
Price
$0.95
Fair Value
-$0.39
Undervalued by
342.60%
CGC ($0.95) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGC ($0.95) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CGC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CGC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.48x
Industry
-4.93x
Market
7.68x
CGC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.79x
Industry
1.53x
CGC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGC's financial health
Profit margin
Revenue
$51.6M
Net Income
-$113.9M
Profit Margin
-220.5%
CGC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CGC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$810.7M
Liabilities
$305.2M
Debt to equity
0.6
CGC's short-term assets ($383.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGC's short-term assets ($383.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CGC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.2M
Investing
-$30.9M
Financing
$33.8M
CGC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGC vs Pharmaceutical Stocks
Canopy Growth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.